Financials data is unavailable for this security.
View more
Year on year AFT Pharmaceuticals Ltd grew revenues 24.75% from 156.64m to 195.41m while net income improved 46.51% from 10.65m to 15.61m.
| Gross margin | 45.17% |
|---|---|
| Net profit margin | 7.99% |
| Operating margin | 12.40% |
| Return on assets | 9.96% |
|---|---|
| Return on equity | 19.38% |
| Return on investment | 13.72% |
More ▼
Cash flow in NZDView more
In 2024, AFT Pharmaceuticals Ltd increased its cash reserves by 265.85%, or 8.75m. The company earned 28.86m from its operations for a Cash Flow Margin of 14.77%. In addition the company used 9.53m on investing activities and also paid 10.63m in financing cash flows.
| Cash flow per share | 0.168 |
|---|---|
| Price/Cash flow per share | 15.12 |
| Book value per share | 0.8372 |
|---|---|
| Tangible book value per share | 0.3274 |
More ▼
Balance sheet in NZDView more
| Current ratio | 2.30 |
|---|---|
| Quick ratio | 1.23 |
| Total debt/total equity | 0.3667 |
|---|---|
| Total debt/total capital | 0.2683 |
More ▼
Growth rates in NZD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 45.45% and 46.51%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 10.89% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 46.51 |
More ▼
